In another study, the combination of vorinostat and letrozole (an aromatase inhibitor) led to inhibited breast cancer cell proliferation, apoptosis, and differentiation of peripheral blood mononuclear cells into osteoclasts. Here, CYP19A1 is linked to breast cancer.